Delivery Order SPE2DB20D2104-SPE2DB23FQ89Y

Award Date 10/28/22
Potential Completion Date 10/31/22
Potential Value $3.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The $3,948.09 firm fixed-price delivery order is for the drug BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, with a performance period through May 13, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,662.45 Firm Fixed Price Delivery Order contract is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of February 27, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,561.60 firm fixed-price delivery order is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medication used for the treatment of type 2 diabetes. The contract has an ultimate completion date of October 28, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,453.28, is a Firm Fixed Price Delivery Order for the medical product "BYDUREON BCISE 2 MG AUTOINJECT 0.85ML". The contract has an ultimate completion date of November 22, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award to Amerisourcebergen Drug Corp. (a major pharmaceutical distributor) by the Defense Logistics Agency (DLA) is for the delivery of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product. The fixed-price delivery order contract has a ceiling value of $4,628.04 and a completion date of July 10, 2023. This award is a part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $20,548.32 firm fixed-price delivery order is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medication used in the treatment of diabetes. The contract has an ultimate completion date of June 24, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of Bydureon BCISE 2 mg autoinjector 0.85 ml. The $5,662.56 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, on May 25, 2023, with a completion date of May 26, 2023. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Bydureon BCISE 2 mg autoinjector 0.85 ml. The $7,360.40 fixed-price delivery order has a completion date of May 8, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, running through November 2026, which serves as a...
This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,308.31 firm fixed price delivery order is for the supply of Bydureon Bcise, a 2 mg autoinjected medication used to treat type 2 diabetes. The contract has a completion date of June 27, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $10,563.44, is a delivery order contract for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product. The contract has an ultimate completion date of July 22, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB23FQ89Y
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,523.40 firm fixed-price delivery order is for the procurement of the medication BYDUREON BCISE 2 MG AUTOINJECT 0.85ML.

Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.

This contract award was not designated with any set-aside requirements, indicating open competition. It has an ultimate completion date of October 31, 2022.

Generated 2/27/25, 10:02 AM